De Saint Basile Hortense, Elaidi Reza, Maaradji Zineb, Blons Hélène, BenDhiab Rym, Gibault Laure, Fabre Elizabeth
Department of Thoracic Oncology, Georges Pompidou European Hospital, Paris Cité University, AP-HP, CARPEM, 75015 Paris, France.
Department of Thoracic Oncology, Georges Pompidou European Hospital, 75015 Paris, France.
Explor Target Antitumor Ther. 2024 Dec 18;5(6):1435-1449. doi: 10.37349/etat.2024.00283. eCollection 2024.
Immune checkpoint inhibitors improved the survival of advanced non-small cell lung cancer. However, only 20% of patients respond to these treatments and the search for predictive biomarkers of response is still topical. The objective of this work is to analyze the anti-PD-1 monotherapy benefit based on genetic alterations diagnosed by next generation sequencing (NGS), in advanced non-small cell lung cancer.
Patients with advanced non-small cell lung cancer treated with immunotherapy were retrospectively included in this monocentric study. Clinical data, immunohistochemical expression of PD-L1 and molecular data, with a 22-genes NGS panel, were collected.
107 patients were included. The median age was 65 years [59; 73], 70 were men (65%), 96 had adenocarcinoma (90%), 33 were receiving a first line (31%). 54 patients had KRAS mutation (50%) and 56 had TP53 mutation (52%). The remaining mutations were present in fewer than 10 patients. There was no statistically significant differences in median of progression-free or overall survival based on KRAS-only, TP53-only or KRAS-TP53 mutations co-mutated compared to double wild-type patients ( = 0.46 and = 0.72 respectively).
The search for a predictive composite biomarker remains a major issue in the coming years.
免疫检查点抑制剂提高了晚期非小细胞肺癌患者的生存率。然而，只有20%的患者对这些治疗有反应，寻找反应的预测生物标志物仍然是热门话题。这项工作的目的是分析基于下一代测序（NGS）诊断的基因改变的抗PD-1单药治疗在晚期非小细胞肺癌中的益处。
接受免疫治疗的晚期非小细胞肺癌患者被回顾性纳入这项单中心研究。收集临床数据、PD-L1的免疫组化表达以及使用22基因NGS panel检测的分子数据。
纳入107例患者。中位年龄为65岁[59；73]，70例为男性（65%），96例为腺癌（90%），33例接受一线治疗（31%）。54例患者有KRAS突变（50%），56例有TP53突变（52%）。其余突变在不到10例患者中出现。与双野生型患者相比，仅KRAS、仅TP53或KRAS-TP53共突变患者的无进展生存期或总生存期的中位数无统计学显著差异（分别为 = 0.46和 = 0.72）。
在未来几年，寻找预测性复合生物标志物仍然是一个主要问题。
